Stallion India Fluorochemicals Limited announces a new order win

The closest reported figure is Rs 34.69 Crores of CWIP in FY26 ^[1]. However, the cited disclosures do not establish that the full Rs 34.69 Crores was transferred to fixed assets for the Khalapur semiconductor-gas facility. Fixed assets increased from Rs 17.21 Crores in FY25 to Rs 65.60 Crores in FY26—an increase of Rs 48.39 Crores, derived from the reported balances ^[2]—but this cannot be attributed entirely to the facility without the project-wise capex note.

The facility filing only states that it was funded through the capital-expenditure requirements disclosed in the January 2026 prospectus; it does not state the facility’s project cost or the amount of CWIP capitalised ^[3]. The facility commenced commercial operations on 21 September 2026 ^[3].

Margin guidance: management’s EBITDA-margin guidance for the semiconductor-grade or specialty gases versus the legacy fluorochemical portfolio is not reported in the cited material. The available financial data is company-wide: FY26 EBITDA was Rs 61.35 Crores on revenue of Rs 430.67 Crores, implying a derived EBITDA margin of 14.24% ^{[4] [5]}. No segment-level EBITDA margin or management target is provided for either the new semiconductor-gas business or the legacy fluorochemical portfolio. Therefore, the claim that the new gases will carry a higher margin profile remains unquantified rather than an evidenced management guide.

The break-even utilization timeline cannot be quantified from the cited filings. The facility’s installed capacity is 1,200 MT per annum, and commercial operations commenced on 21 September 2026 ^[3]. However, the disclosed operational update does not state the earlier utilization ramp targets, fixed-cost base, contribution margin per MT, or the utilization level at which the facility becomes EBITDA- or PAT-positive.

What can be concluded

• The project was fully installed by end-August 2026, underwent commissioning and trial runs in the first week of September, and was scheduled to begin commercial production on 21 September 2026 ^[6].
• The facility is therefore entering its operating ramp from September 2026, but the evidence does not support a precise conclusion such as “break-even within 12 months” or “by FY28.”
• On the depreciation question, the filing links the facility to capital expenditure disclosed in the January 2026 Prospectus but does not disclose the asset’s useful life, depreciation method, annual depreciation charge, or exact depreciation commencement date ^[3].
• Commercial commencement means depreciation will become relevant to the facility’s reported operating economics from the point the assets are available for use under the company’s accounting policy. Accordingly, cash or contribution break-even could occur before accounting break-even, because depreciation is a non-cash fixed cost; PAT break-even would require covering depreciation as well.

Analyst read

The correct interpretation is a ramp-period mismatch risk: early utilization may generate positive contribution while still producing an accounting loss if the 1,200 MT capacity is under-absorbed and depreciation is charged from commissioning or commercial availability. A defensible break-even date requires the earlier utilization target and the facility-level cost assumptions from the Prospectus or subsequent financial disclosures. Those figures, along with the depreciation schedule, are not stated in the cited materials, so no evidence-backed timeline can be assigned.

No quantified revenue contribution from high-purity semiconductor-grade gases has been disclosed. The Khalapur facility commenced commercial operations on 21 September 2026 with an installed capacity of 1,200 MT per annum in aggregate for debulking and blending semiconductor and specialty gases; the filing does not split capacity between semiconductor-grade and other specialty gases, nor provide utilization, pricing, customer volumes or revenue guidance. ^[3]

Peer comparison

The comparison is therefore not like-for-like. Stallion has disclosed a physical capacity addition but not its revenue run-rate, while Navin and SRF report broader chemical segments rather than a separately identifiable “specialty gas” revenue pool. SRF’s Chemicals Business also includes fluorochemicals and specialty chemicals, so its 46.0% share should not be interpreted as specialty-gas contribution. ^[8]

Analytical implication: the facility represents a product-mix shift toward higher-specification gases, but the financial magnitude remains an execution-dependent option rather than a quantified revenue stream. A credible contribution estimate would require at least the semiconductor-gas capacity split, average realization per MT, ramp-up schedule and customer qualification status. The currently disclosed 1,200 MT capacity should not be converted into revenue without those inputs.